Home
NewsNewsASEAN's First Telemedicine IVF by Inspire IVF introduces a new era of remote fertility care. Combining AI technology with expert consultation, the platform enables global access, real-time monitoring, and personalised treatment planning, positioning Thailand as a leading hub for fertility services and advancing digital transformation in reproductive healthcare.
Inspire IVF Public Company Limited (“IVF”), recognized as a premier comprehensive fertility treatment centre in Asia, has officially announced the launch of the “Inspire IVF Telemedicine Service". This pioneering remote fertility care platform is designed to seamlessly integrate advanced Artificial Intelligence (AI) technology with a world-class team of expert medical professionals. The primary goal of this initiative is to deliver continuous, high-quality patient care to individuals regardless of their geographical location. This milestone solidifies the company’s position as the developer of ASEAN's First Telemedicine IVF, leveraging cutting-edge digital technology to enhance infertility treatment and expand international access to sophisticated medical services.
The “Inspire IVF Telemedicine Service” was developed under the guiding principle of “Simplicity in Every Step.” This philosophy aims to streamline the often complex treatment process, significantly improve accessibility to specialised medical teams, and provide a more personalised, continuous experience for patients. The platform is particularly transformative for patients residing in various provinces within Thailand, as well as international patients who wish to meticulously plan their treatment journey before arriving in the country.
By introducing ASEAN's First Telemedicine IVF, Inspire IVF is addressing a critical global health trend. Ms. Kasinee Kuldiloke, Chief Executive Officer of Inspire IVF Public Company Limited, highlighted the urgency of this innovation by stating, "Infertility is increasingly recognized as a global health challenge. Data from the World Health Organization (WHO) indicates a worldwide rise in infertility, with the number of affected individuals increasing by over 20% in the past 30 years. This has led to a sustained demand for quality and accessible treatment services. However, many patients continue to face barriers such as distance, time constraints, and limited access to specialized doctors. Addressing these challenges, Inspire IVF has developed the 'Inspire IVF Telemedicine Service' to allow patients to initiate treatment planning, consult with doctors, and monitor their progress from any location worldwide.”
The service is engineered to enhance the overall fertility treatment experience through several innovative features:
Ms Kasinee elaborated that this technology transcends being a mere tool; it represents an evolution in care that aligns with modern digital lifestyles. For example, couples abroad can review test results and receive preliminary advice through the online system, reducing the need for multiple trips and saving significant time.
Inspire IVF distinguishes itself through international benchmarks for quality and safety. It is the first specialized fertility clinic in the Asia Pacific region to receive both AACI (American Accreditation Commission International) and ISO 9001 certifications from the United States. Furthermore, it holds the distinction of being the first IVF centre in Southeast Asia to achieve TEMOS certification from Germany. This specific standard evaluates the quality of medical services for international patients, demonstrating that the centre's medical personnel and service standards rival leading medical centres globally.
Due to these rigorous standards, the centre achieves a high success rate of 70–76% for eligible patients, consistently elevating the quality of treatment in line with international benchmarks.
The launch of ASEAN's First Telemedicine IVF is a crucial component of positioning Thailand as a primary Medical Hub for Fertility Care. By allowing global patients to begin treatment planning from their home countries, the service boosts fertility tourism potential and enhances the efficiency of the medical process. Ultimately, Inspire IVF remains committed to making infertility treatment more accessible and convenient, staying true to its core philosophy of “Simplicity in Every Step.”
As more families pursue fertility treatments, IVF CRYO urges greater transparency and safety in better Safe Embryos and Eggs Shipping across the U.S.
China sees a rise in advanced maternal age In Vitro Fertilization, driven by BaseCare Medical’s AI undisturbed culture system that improves embryo quality and clinical pregnancy rates, especially with PGT. Localized AI-assisted solutions position BaseCare as a leader in smart, precision reproduction technology for older IVF patients.
According to a landmark large-scale IVF trial, using natural ovulation for frozen embryo transfers achieves matching birth rates to standard hormone cycles, offering a safer alternative for women.
IVI RMA North America has launched the IVI RMA Patient Advisory Council in the US and Canada to strengthen patient-centered care. The councils bring patients, clinicians, and leadership together in structured monthly discussions, ensuring real patient experiences inform fertility care improvements, service innovation, and long-term clinical strategies.
Conceivable Life Sciences' AURA, world's first AI-powered automated IVF lab, has successfully delivered 18 healthy babies since April 2025. The revolutionary robotic system automates 200+ IVF steps with unprecedented precision, promising to make fertility treatment more accessible, affordable, and consistent while eliminating human error in embryo creation.
Infertility Treatment Drugs from Merck have enabled the births of 6 million babies globally, with 50% of conceived individuals tied to its therapies.
EMD Serono will offer steep IVF drug discounts via TrumpRx.gov in 2026 and seek expedited FDA review for Pergoveris, aligning with a White House order.
